Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Clinical Data for Demcizumab at the European Lung Cancer Conference

REDWOOD CITY, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18)...
April 02, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer

REDWOOD CITY, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
March 19, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting

REDWOOD CITY, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
March 12, 2015 16:02 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent Highlights

REDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
March 03, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Report Full Year and Fourth Quarter 2014 Financial Results on Thursday, March 12, 2015

REDWOOD CITY, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
February 04, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 29, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

FDA Grants Orphan Drug Designations to OncoMed's Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer

REDWOOD CITY, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 28, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February

REDWOOD CITY, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 16, 2015 14:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium

Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients Median Progression-Free Survival of 6.6 Months in Tumor Notch3 High Patients and 5.6 Months in...
January 15, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in Solid Tumors

REDWOOD CITY, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...